Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dojindo Laboratories currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, CLARKE, TRENT R, within 1 distinct art unit. CLARKE, TRENT R is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This represents a concentrated prosecution profile where 1 distinct examiner and 1 distinct art unit define the current landscape.
The focus on 1 distinct examiner within the Biotechnology & Pharmaceuticals field allows for a specific prosecution approach. Because there is only 1 pending office action, the company can dedicate its resources to addressing the specific concerns of CLARKE, TRENT R. The involvement of 1 distinct art unit suggests that the technology is classified within a single specialized group. This simplicity in the portfolio structure reduces the complexity of managing multiple examiner interactions. Practitioners can expect a consistent dialogue with the patent office given that 1 busiest examiner pending action accounts for the entire workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CLARKE, TRENT R | 1 | 42.0% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18460688 | METHOD FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, KIT FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, METHOD FOR DETERMINING SELENOCYSTEINE, AND KIT FOR DETERMINING SELENOCYSTEINE | CLARKE, TRENT R | 15d |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18460688 | METHOD FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, KIT FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, METHOD FOR DETERMINING SELENOCYSTEINE, AND KIT FOR DETERMINING SELENOCYSTEINE | CLARKE, TRENT R | 1651 | §103 | Final Rejection | 15d | Pending | Sep 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial